TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Need for pharmacological intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Clinical outcomes of LLLT (PBM) intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight loss effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Losing >5% weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete bone fusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Separation from parents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Face mask acceptance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual field mean deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean vertical cup-to-disc ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Entropy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Central Foveal Thickness (CFT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Best Corrected Visual Acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Height of Subretinal Fluid (SRD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Immunogenicity (seroconversion, seroprotection, GMT ratios)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: suture dehiscence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Area under the 120‐h serum insulin degludec concentration‐time curve (AUC120 h)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum insulin degludec concentration (C max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance covered by the 6MWT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leg extensor muscles MVC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total frequency of PONV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of rescue antiemetic usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FMA scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: whole blood stimulated leukotriene LTB4 at trough drug level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: urine leukotriene LTE4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: reduction in noncalcified plaque volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Permanent neurologic deficits
Endpoint domain: Adverse events/effects
Primary endpoint: Sustained LDR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nocebo hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Onset latency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Arousals
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: overall survival after OLT
Endpoint domain: Mortality/survival
Primary endpoint: partial tumor response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of progression of Parkinson's Disease (PD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ear discomfort during hyperbaric oxygen therapy
Endpoint domain: Adverse events/effects
Primary endpoint: VP shunt placement or death
Endpoint domain: Mortality/survival
Primary endpoint: Stroke or systemic embolic event
Endpoint domain: Mortality/survival
Primary endpoint: Post retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in papillae
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CVD risk association with polyunsaturated phosphatidylcholines and cholesterol esters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CVD risk association with monoacylglycerols, diacylglycerols, and triacylglycerols
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to achieve normothermia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physician-patient communication
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 1/HOMA‐IR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of closed fractures healed at four months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of additional procedures performed to obtain union
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Gastric area after meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Death during study treatment
Endpoint domain: Mortality/survival
Primary endpoint: Positive urine test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days using drug in the past week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: standard base excess
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum bicarbonate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Protein binding of sufentanil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protein binding of hydromorphone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative TnI release
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: success rates at 18 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Positive sentinel lymph node (SLN) identification rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proinflammatory cytokine levels (IL-6 and MCP-1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: nalbuphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of patients requiring intra‐operative fentanyl
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall 3-year survival
Endpoint domain: Mortality/survival
Primary endpoint: Disease-free 3-year survival
Endpoint domain: Mortality/survival
Primary endpoint: major access-site bleeding (ASB)
Endpoint domain: Adverse events/effects
Primary endpoint: Serum VZV antibody titres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum 8‐isoprostane levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: erythrocyte superoxide dismutase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lag time to oxidation of LDL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Mean difference in log10 viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients' perception of esthetic outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Color difference of peri-implant mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental component scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Skin conductance responses during extinction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: bone relapse free survival
Endpoint domain: Mortality/survival
Primary endpoint: Total truncal pressure ulcer surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Decrease in stage IV ulcer area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Adjusted mean Hb increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum ferritin values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of time per patient with temperature >38 degrees C
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean T degrees
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: max T degrees
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Appropriate follow-up recorded
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurological improvement at 72 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Minimal or absent disability at 3 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Nitric oxide concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: treatment efficacy in patients with medication-resistant major depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: efficacy scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QuickDash score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Blood serum CK‐MB levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Blood serum cTn I levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Co-occurring general medical conditions awareness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Behavior following waking score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Interrater agreement in diagnosing pupillary dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First passing of flatus-defecation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Non-adhesion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Primary patency rates at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in clinical, endoscopic, and histological grades
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All-cause mortality in residents
Endpoint domain: Mortality/survival
Primary endpoint: Influenza-like illness (ILI) in residents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sick leave from work in staff
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 75% improvement in psoriasis area‐and‐severity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative air leaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VO2 improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Quality of working memory
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Spatial working memory accuracy
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Termination of fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of return of organized rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postdinner glucose excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nocturnal IG fluctuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nocturnal high IG episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Blood iron levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of anaemic women
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Aqueous PGE(2) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aqueous concentrations of ketorolac and bromfenac
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to first skeletal-related event
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Release of cardiac troponin I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: intrabony defect reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MOS-HIV summary score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Symptom Distress Scale scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: clinical recurrence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AC and CC distances
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prevalence of parasympathetic dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of sympathetic dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Advanced adenoma recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Voluntary energy intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Resumption of recreational activities
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: serum 1,25(OH)2D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: serum 25(OH)D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: A95 (postural stability)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COP path length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in limb fat percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urogenital distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increased natriuresis and diuresis overnight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Increase in ANP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: severity of vaginal dryness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of episode-free days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean increase in height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the number of silent ischemic ST change vector magnitude episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in the duration of silent ischemic ST change vector magnitude episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean daily bowel frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Scores for stool consistency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Ease of evacuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Completeness of Cytoreduction (CC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: ALT elevation resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: vision-related function score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: health-related QoL scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: IT behavior rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: future intentions
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to first response on Clinical Global Impressions‐Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specific T-cell hyporesponsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum-specific IgG4 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cytokine modulation (IL-10 and IFN-gamma secretion)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Tolerance to ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Peak endotoxaemia level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Specific IgM response to endotoxins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Pregnancy loss
Endpoint domain: Mortality/survival
Primary endpoint: Time to pregnancy (TTP)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean angle width (modified Shaffer grade)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean anterior chamber area (ACA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean anterior chamber volume (ACV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trough FEV(1) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: TDI increase
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: SGRQ total score decrease
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: futile thoracotomy rate
Endpoint domain: Mortality/survival
Primary endpoint: Baroreflex slope
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Median time to airway access
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to first manikin contact
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Median time to standard position for CPR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Allergic contact dermatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: treatment discontinuation rate
Endpoint domain: Mortality/survival
Primary endpoint: mean time to all-cause discontinuation
Endpoint domain: Mortality/survival
Primary endpoint: Resolution of papilledema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in foot function (AOFAS scores)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2-year efficacy of teberif
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain interference with function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: immunization status improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-year actuarial local control
Endpoint domain: Mortality/survival
Primary endpoint: 3-year actuarial disease-free survival
Endpoint domain: Mortality/survival
Primary endpoint: 3-year actuarial risk of developing any Grade 3 or worse late toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Effectiveness of sweat testing for monitoring MDMA use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean FPG reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: soluble P-selectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Objective physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self‐ and collective‐efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Pulmonary artery index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ascending colon transit time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Stool water content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Quinine absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Failure rate of nonoperative treatment
Endpoint domain: Mortality/survival
Primary endpoint: New segmental LV wall motion abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to sit on the edge of bed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to resume intestinal transit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: skills retention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronary flow velocity reserve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Postoperative MMSE values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes